IONIS PHARMACEUTICALS INC (IONS) Form 8-K — Jul 29, 2026
Ionis Pharmaceuticals reported financial results for the second quarter of 2026, with total revenue of $268 million. Excluding a one-time payment received in the prior year, revenue increased 56% year-over-year driven by product sales and royalties, though the company recorded a net loss of $115 million compared to net income of $124 million in the prior year quarter. Cash, cash equivalents and short-term investments were $2.1 billion as of June 30, 2026, down from $2.7 billion at year-end 2025 due to debt repayment. Commercial momentum continued with DAWNZERA generating $26 million in net product sales and TRYNGOLZA contributing $5 million following its recent approval.
Key figures
- Revenue
- 268
- Cash Position
- 2055
- Dawnzera sales q2 millions
- 26
- Wainua royalty q2 millions
- 16
- Tryngolza sales q2 millions
- 5
- Spinraza royalty q2 millions
- 54
- Cardio ttransform primary endpoint
- missed
Price after filing
Close on the filing date to close N calendar days later (from $55.96). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.